skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.08d (Release date: 2017-08-28)
SearchBox Top
SearchBox Bottom
Lonaprisan (Code C71532)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Lonaprisan

Definition: An orally bioavailable pentafluoroethyl derivative of a mifepristone-related steroid with antiprogestagenic activity. Lonaprisan is a pure, highly receptor-selective progesterone receptor (PR) antagonist; binding of this agent to PRs inhibits PR activation and the associated proliferative effects. Unlike many other antiprogestins such as mifepristone, this agent does not appear to convert to an agonist in the presence of protein kinase A (PKA) activators and shows high antiprogestagenic activity on both progesterone receptor (PR) isoforms PR-A and PR-B.

Label: Lonaprisan

NCI Thesaurus Code: C71532 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2347691  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
11 beta-(4-acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-17 alpha-pregna-5,9-dien-3-one
Progesterone Receptor Antagonist ZK 230211
ZK 230211

External Source Codes: 
CAS Registry Number 211254-73-8 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 579241
PDQ Open Trial Search ID 579241 (check for NCI PDQ open clinical trial info)
PubMedID Primary Reference 11150172 (see PubMed Primary Reference info)
UMLS CUI C2347691

Other Properties:
     Name Value (qualifiers indented underneath)
Accepted_Therapeutic_Use_For Treatment of progesterone receptor positive breast cancer
Chemical_Formula C28H29F5O3
code C71532
Contributing_Source FDA
Legacy_Concept_Name Progesterone-Receptor_Antagonist_ZK_230211
Semantic_Type Chemical Viewed Functionally

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom